• Home
  • Press
  • Contact
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar

TearClear logo

Preservative-free ophthalmic drug delivery

  • Home
  • Press
  • Contact

Press Releases

  • 2020
  • 2019
  • 2017
  • Dec 1, 2020
    TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
  • Sep 29, 2020
    TearClear Appoints Robert Bailey to Board of Directors
  • Aug 11, 2020
    TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
  • May 20, 2020
    TearClear appoints Dr. Amir Shojaei Chief Development Officer
  • Apr 15, 2020
    TearClear appoints Robert J. Dempsey Chief Executive Officer
  • May 29, 2019
    TearClear Appoints Chief Scientific and Innovation Officer
  • May 30, 2017
    TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team of Accomplished Ophthalmology Veterans
Facebook0Tweet0LinkedIn0Email0Print0

Primary Sidebar

Press

  • Press Releases
    • TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
    • TearClear Appoints Robert Bailey to Board of Directors
    • TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
    • TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team of Accomplished Ophthalmology Veterans
    • TearClear appoints Robert J. Dempsey Chief Executive Officer
    • TearClear appoints Dr. Amir Shojaei Chief Development Officer
    • TearClear Appoints Chief Scientific and Innovation Officer
  • In the News
  • Interviews
  • Downloads

Copyright © 2017–2021 TearClear Corp · All Rights Reserved · Design and development by Sky Dog Technologies

Share this ArticleLike this article? Email it to a friend!

Email sent!